Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 178
- Registration Number
- NCT03776812
- Locations
- ๐บ๐ธ
Site Reference ID/Investigator #038, Scottsdale, Arizona, United States
๐ง๐ชSite Reference ID/Investigator #109, Brussel, Belgium
๐ง๐ชSite Reference ID/Investigator #108, Leuven, Belgium
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
- First Posted Date
- 2018-10-05
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 152
- Registration Number
- NCT03697109
- Locations
- ๐บ๐ธ
Site 41, Chicago, Illinois, United States
๐บ๐ธSite 46, Boston, Massachusetts, United States
๐บ๐ธSite 7, Indianapolis, Indiana, United States
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 125
- Registration Number
- NCT03604198
- Locations
- ๐บ๐ธ
Site 3, Saint Louis, Missouri, United States
๐บ๐ธSite 55, Reno, Nevada, United States
๐บ๐ธSite 2, Pittsburgh, Pennsylvania, United States
A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants
- Conditions
- Interventions
- First Posted Date
- 2018-05-30
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT03540836
- Locations
- ๐บ๐ธ
Celerion, Tempe, Arizona, United States
Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites
- Conditions
- Interventions
- First Posted Date
- 2018-04-30
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 52
- Registration Number
- NCT03512548
- Locations
- ๐บ๐ธ
Celerion, Tempe, Arizona, United States
CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)
- Conditions
- Interventions
- First Posted Date
- 2018-04-26
- Last Posted Date
- 2019-08-09
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 130
- Registration Number
- NCT03508635
- Locations
- ๐ฌ๐ง
Quotient Clinical, Nottingham, Nottinghamshire, United Kingdom
Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s
- Conditions
- Interventions
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 27
- Registration Number
- NCT03457597
- Locations
- ๐บ๐ธ
Celerion, Tempe, Arizona, United States
Relacorilant Food Effect Study in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT03442621
- Locations
- ๐บ๐ธ
Celerion, Tempe, Arizona, United States
Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC
- Conditions
- Interventions
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 39
- Registration Number
- NCT03437941
- Locations
- ๐บ๐ธ
New York, New York, New York, United States
๐ฌ๐งSouthampton, Southampton, England, United Kingdom
๐บ๐ธScottsdale, Scottsdale, Arizona, United States
Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome
- Conditions
- First Posted Date
- 2017-12-20
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 2
- Registration Number
- NCT03379363
- Locations
- ๐บ๐ธ
Corcept Therapeutics, Menlo Park, California, United States